Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib + Temozolomide in Advanced Solid Tumors
NCT03150810Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of pamiparib in solid tumor, gastric cancer (GC), ovarian cancer and 6 more (13 arms), sponsored by BeiGene. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and 1 more. Started Jun 2017; status: completed.
02
Drugs
pamiparib
03
Conditions
solid tumorgastric cancer (GC)ovarian cancersmall cell lung cancer (SCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03150810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150810.